SK bioscienceLtd Valuation

Is A302440 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A302440 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate A302440's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate A302440's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A302440?

Key metric: As A302440 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for A302440. This is calculated by dividing A302440's market cap by their current revenue.
What is A302440's PS Ratio?
PS Ratio	9x
Sales	₩399.83b
Market Cap	₩3.59t

A302440 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	7.6x
Enterprise Value/EBITDA	-47.3x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does A302440's PS Ratio compare to its peers?

The above table shows the PS ratio for A302440 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	28.4x
A145020 Hugel	8.8x	18.28%	₩3.4t
A214450 PharmaResearch	14.8x	27.32%	₩5.8t
A007390 NatureCellLtd	89.1x	n/a	₩2.4t
A006280 GC Biopharma	1x	8.67%	₩1.7t
A302440 SK bioscienceLtd	9x	18.68%	₩3.6t

Price-To-Sales vs Peers: A302440 is good value based on its Price-To-Sales Ratio (9x) compared to the peer average (28.4x).

Price to Sales Ratio vs Industry

How does A302440's PS Ratio compare vs other companies in the KR Biotechs Industry?

28 Companies	Price / Sales	Estimated Growth	Market Cap
A006280 GC Biopharma	1x	8.67%	US$1.19b
A096530 Seegene	3.1x	15.01%	US$981.96m
A086900 Medy-Tox	4.3x	15.03%	US$740.34m
A005250 Green Cross Holdings	0.3x	n/a	US$523.09m

28 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: A302440 is good value based on its Price-To-Sales Ratio (9x) compared to the KR Biotechs industry average (14.6x).

Price to Sales Ratio vs Fair Ratio

What is A302440's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A302440 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	9x
Fair PS Ratio	3.9x

Price-To-Sales vs Fair Ratio: A302440 is expensive based on its Price-To-Sales Ratio (9x) compared to the estimated Fair Price-To-Sales Ratio (3.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst A302440 forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	₩45,750.00	₩36,000.00 -21.31%	13.75%	₩43,000.00	₩30,000.00	n/a	4
Jul ’26	₩48,400.00	₩34,750.00 -28.20%	19.13%	₩43,000.00	₩25,000.00	n/a	4
Jun ’26	₩45,100.00	₩34,750.00 -22.95%	19.13%	₩43,000.00	₩25,000.00	n/a	4
May ’26	₩39,600.00	₩44,000.00 +11.11%	28.86%	₩60,000.00	₩25,000.00	n/a	5
Apr ’26	₩39,450.00	₩48,500.00 +22.94%	20.58%	₩60,000.00	₩37,000.00	n/a	6
Mar ’26	₩42,550.00	₩48,500.00 +13.98%	20.58%	₩60,000.00	₩37,000.00	n/a	6
Feb ’26	₩49,000.00	₩48,833.33 -0.34%	19.76%	₩60,000.00	₩37,000.00	n/a	6
Jan ’26	₩50,400.00	₩48,833.33 -3.11%	19.76%	₩60,000.00	₩37,000.00	n/a	6
Dec ’25	₩47,100.00	₩49,333.33 +4.74%	18.42%	₩60,000.00	₩40,000.00	n/a	6
Nov ’25	₩52,800.00	₩49,333.33 -6.57%	18.42%	₩60,000.00	₩40,000.00	n/a	6
Oct ’25	₩55,400.00	₩46,800.00 -15.52%	22.51%	₩60,000.00	₩35,000.00	n/a	5
Sep ’25	₩55,500.00	₩46,800.00 -15.68%	22.51%	₩60,000.00	₩35,000.00	n/a	5
Aug ’25	₩55,500.00	₩57,000.00 +2.70%	31.99%	₩89,000.00	₩35,000.00	₩45,750.00	7
Jul ’25	₩53,800.00	₩57,714.29 +7.28%	30.57%	₩89,000.00	₩35,000.00	₩48,400.00	7
Jun ’25	₩51,700.00	₩58,000.00 +12.19%	29.95%	₩89,000.00	₩35,000.00	₩45,100.00	7
May ’25	₩58,600.00	₩58,000.00 -1.02%	29.95%	₩89,000.00	₩35,000.00	₩39,600.00	7
Apr ’25	₩61,800.00	₩56,428.57 -8.69%	33.94%	₩89,000.00	₩31,000.00	₩39,450.00	7
Mar ’25	₩61,400.00	₩56,428.57 -8.10%	33.94%	₩89,000.00	₩31,000.00	₩42,550.00	7
Feb ’25	₩64,100.00	₩56,428.57 -11.97%	33.94%	₩89,000.00	₩31,000.00	₩49,000.00	7
Jan ’25	₩72,000.00	₩58,625.00 -18.58%	31.18%	₩89,000.00	₩33,000.00	₩50,400.00	8
Dec ’24	₩67,800.00	₩58,625.00 -13.53%	31.18%	₩89,000.00	₩33,000.00	₩47,100.00	8
Nov ’24	₩60,700.00	₩58,625.00 -3.42%	31.18%	₩89,000.00	₩33,000.00	₩52,800.00	8
Oct ’24	₩67,700.00	₩62,857.14 -7.15%	31.13%	₩98,000.00	₩35,000.00	₩55,400.00	7
Sep ’24	₩72,100.00	₩61,250.00 -15.05%	30.68%	₩98,000.00	₩35,000.00	₩55,500.00	8
Aug ’24	₩77,400.00	₩61,250.00 -20.87%	30.68%	₩98,000.00	₩35,000.00	₩55,500.00	8

AnalystConsensusTarget

Consensus Narrative from 4 Analysts

₩36.00k

Fair Value

27.1% overvalued

Number of Analysts

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/07/31 00:21
End of Day Share Price	2025/07/31 00:00
Earnings	2025/03/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

SK bioscience Co.,Ltd. is covered by 9 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Hyonseok Kim	CLSA
Sunghwan Kim	Credit Suisse
null null	Credit Suisse